Your session is about to expire
← Back to Search
HEART Camp Connect for Heart Failure
Study Summary
This trial tests if HEART Camp Connect can improve long-term adherence to exercise in individuals with heart failure. It includes 4 data collection points and instruments collected over 12 weeks. Interviews at 12 weeks also included.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have had a heart attack, heart surgery, or a pacemaker implanted less than 6 weeks ago.You have been regularly doing aerobic exercise (like running or swimming) three times a week for the past six months.You have a condition in your bones or muscles that makes it difficult for you to do aerobic exercise.You have a condition called unstable angina, which means your chest pain is not stable or predictable.You have severe heart failure that is not well controlled.
- Group 1: HEART Camp Connect
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the total patient population for this trial?
"Affirmative. According to information found on clinicaltrials.gov, this medical research project is enrolling participants at the present time; it was first posted on June 1st 2022 and most recently revised in March 6th 2023. The trial requires 10 individuals from 1 site for inclusion."
Is the enrollment period for this trial currently active?
"According to clinicaltrials.gov, this experiment is actively seeking participants; its initial posting date was June 1st 2022 and the trial's most recent update occurred on March 6th 2023."
Share this study with friends
Copy Link
Messenger